DAWEX
8.2.2024 08:31:33 CET | Business Wire | Press release
Today marks the signature of Data4Industry-X, the trusted, secure, compliant and sovereign data exchange environment for the Industry sector, under the control of the industry. Initially addressing the automotive and power generation industry challenges, the solution Data4Industry-X aims at improving competitiveness and reducing the carbon footprint of major global industrial organizations with operations spread across multiple countries. Data4Industry-X will enable organizations to innovate and operate services on distributed data, coming from various factories, organizations or countries, while keeping control over the data produced locally and abroad.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240205958581/en/
The Trusted Data Exchange Solution for Industry (Credits: Dawex)
Supported by the French government’s France 2030 initiative and the European program Next Generation1, and with the endorsement of AIF (Alliance pour l’industrie du futur), Data4Industry-X relies on the technological and industrial expertise of Dawex, Schneider Electric, Valeo, CEA, and Prosyst to deliver a powerful response to support the Industry digital transformation and capitalize on the high potential of industrial data.
Contributing to the international Manufacturing-X initiative, Data4Industry-X is a trusted and secure data exchange solution, implementing the Gaia-X de facto standards and designed in compliance with the new European data regulations, such as the Data Act.
Addressing the Industry challenge of data exchange in decentralized manufacturing, Data4Industry-X will improve efficiency and productivity, accelerate data-driven innovation, boost competitiveness and minimize carbon footprint.
In a context of heavy digital transformation and industrial sovereignty, Data4Industry-X will contribute to improving Europe’s competitiveness to ultimately foster a compelling and sustainable Industry ecosystem by leveraging the full potential of broad cross-border, cross-company, cross-factory industrial data exchanges.
“The Industry sector is a strategic pillar to the European and global economy. Accelerating data exchange across trusted data spaces will definitely have a transformative impact on industrial organizations, driving innovation and responsible growth,” said Laurent Lafaye, Dawex co-CEO. “We are extremely happy to bring Dawex technology and expertise to the deployment of Data4Industry-X, and empower the Industry to foster a resilient and sustainable Industry ecosystem,” concluded Mr. Lafaye.
“Trusted data exchange is fundamental to driving collaboration, forging partnerships, and establishing new industrial models. Those new digital models are essentials for accelerating the transformation toward a more resilient, sustainable, and high-performing industrial eco-system. Schneider Electric takes pride in contributing with our industrial digital transformation expertise to develop Data4Industry-X as a flagship project of International Manufacturing-X,“ said Marc LAFONT, Innovation and Upstream Marketing VP, Industrial Automation Business Unit, Schneider Electric.
Romain Bruniaux, VP Industry, Valeo said: “Data4Industry-X is a collaborative trusted and secure data exchange solution, It offers amazing opportunities to speed up digitalization of our manufacturing process while drastically reducing our scope 1 & 2 CO2 direct and indirect emissions. With Data4Industry-X, Valeo will have the necessary data to support and direct its actions to meet our commitment to be carbon neutral by 2050.”
“Data4Industry-X capitalizes on national technologies that have already proved their worth in industry. Given the international state of the art in the field, with few operational tools known to date, Europe has a chance to take the lead in data exchange for Manufacturing,” said Alexandre Bounouh, Director CEA List, Carnot Institute.
“Collective intelligence, shared vision, teams’ symbiosis: the ingredients come together for the success of Data4Industry-X,” says Abdallah Asse, Prosyst CEO.
About Dawex
Dawex is the leader in data exchange solutions to distribute or share data products, with trust, for any business case. With the Dawex solution Data Exchange Platform, organizations create data ecosystems based on data marketplaces and data hubs that meet regulatory requirements, address traceability and security challenges. Awarded Technology Pioneer by the World Economic Forum, Dawex is the initiator of an international standardization program on “Trusted Data Transaction”. Created in 2015, Dawex is headquartered in France, expanding business operations to Europe, Asia, North America and the Middle East.
About Schneider Electric
Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On. Our mission is to be your digital partner for Sustainability and Efficiency. We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries. We are the most local of global companies. We are advocates of open standards and partnership ecosystems that are passionate about our shared Meaningful Purpose, Inclusive and Empowered values. www.se.com
About Valeo
As a technology company and partner to all automakers and new mobility players, Valeo is innovating to make mobility cleaner, safer and smarter. Valeo enjoys technological and industrial leadership in electrification, driving assistance systems, reinvention of the interior experience and lighting everywhere. These four areas, vital to the transformation of mobility, are the Group's growth drivers. Learn more: https://www.valeo.com/en/
About CEA-List
The CEA-List, based in Paris-Saclay and Grenoble, is a CEA technology research institute dedicated to intelligent digital systems. From artificial intelligence to digital trust, its research applies to a wide range of fields, from the industry of the future to digital health, contributing to the industrial competitiveness of its partners through innovation and technology transfer. CEA-List has been a "Carnot Institute" since 2006. Learn more: https://www.cea.fr/english
About Prosyst
Prosyst develops and markets innovative solutions (hardware and software) stimming from its strong commitment in Research and Development and offers global approaches for design, setup, simulation, data collect and management, diagnosis and performance, to support its customers all along the automated systems life cycle. Prosyst addresses all sectors of activity and counts among others, clients like Stellantis, Renault, SNCF, EDF, Naval Group, … Learn more: https://www.prosyst.fr/
1Supported by the European Union - Next Generation EU “France Relance” program
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240205958581/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom